Prodrugs and Targeted Delivery - gebonden uitgave, pocketboek

EAN (ISBN-13): 9783527326037
ISBN (ISBN-10): 3527326030
Gebonden uitgave
Verschijningsjaar: 2010
Uitgever: Rautio, Jarkko, Wiley-VCH
496 Bladzijden
Gewicht: 1,104 kg
Taal: eng/Englisch

Boek bevindt zich in het datenbestand sinds 2007-01-16T12:28:29+01:00 (Amsterdam)
Detailpagina laatst gewijzigd op 2023-09-23T10:37:34+02:00 (Amsterdam)
ISBN/EAN: 3527326030

ISBN - alternatieve schrijfwijzen:
3-527-32603-0, 978-3-527-32603-7
alternatieve schrijfwijzen en verwante zoekwoorden:
Auteur van het boek: kubinyi, rauti, raimund, hugo, wiley vch, gerd folkers
Titel van het boek: delivery beyond, principles chemistry

---

Gegevens van de uitgever

Auteur: Jarkko Rautio
Titel: Methods and Principles in Medicinal Chemistry; Prodrugs and Targeted Delivery - Towards Better ADME Properties
Uitgeverij: Wiley-VCH; Wiley-VCH
496 Bladzijden
Verschijningsjaar: 2010-12-15
Gedrukt / Gemaakt in
Gewicht: 1,432 kg
Taal: Engels
185,00 € (DE)
190,20 € (AT)
Available
170mm x 240mm x 39mm

BB; Hardcover, Softcover / Chemie; Medizinische Chemie, Pharmazeutische Chemie; Verstehen; Medizin, Gesundheit; Arzneimittelentwicklung; Arzneimittelforschung; Chemie; Chemistry; Drug Discovery & Development; Drug Formulation & Delivery; Toxicology; Toxikologie; Wirkstoff; Wirkstoffformulierung, Wirkstofftransport; Wirkstoffforschung u. -entwicklung; Wirkstoffforschung u. -entwicklung; Wirkstoffformulierung, Wirkstofftransport; Toxikologie

By definition, drugs are highly active substances that are beneficial if they act at the right time and in the right place, but can cause harm otherwise. A clever strategy to ensure that a drug only becomes active when needed is to "camouflage" it. Such camouflaged, i.e. deactivated, drugs that become chemically or biochemically activated once they reach their site of action are called prodrugs. This topical reference and handbook addresses the chemistry, pharmacology, toxicology and the patentability of prodrugs, perfectly mirroring the integrated approach prevalent in today's drug design. It summarizes current experiences and strategies, beginning at the early stages of the development process, while also discussing organ- and site-selective prodrugs. From the contents: * Prodrug design and intellectual property * Prodrugs addressing ADMET issues * Codrugs and soft drugs * Preclinical and clinical consideration for prodrugs This book is a valuable reference for all companies employing medicinal chemists by giving a practice-oriented overview of a key strategy in modern drug discovery and development.